CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Soave, Danilo Figueiredo ^a   Oliveira da Costa, João Paulo ^a   da Silveira, Giorgia Gobbi ^a   Ianez, Renata Carolina Fraga ^b   de Oliveira, Lucinei Roberto ^a   Lourenço, Silvia Vanessa ^a   Ribeiro Silva, Alfredo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

CD44, CD24; Clinicopathologic features; Salivary gland; Salivary gland neoplasm

Indexed keywords

CD24 ANTIGEN; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOMA; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SALIVARY GLAND TUMOR; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; ANTIGENS, CD44; CARCINOMA; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SALIVARY GLAND NEOPLASMS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84873939223     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-29     Document Type: Article

References (57)

1. Lopes MA, Santos GC, Kowalski LP. Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck 1998, 20(8):699-706. 10.1002/(SICI)1097-0347(199812)20:8<699::AID-HED7>3.0.CO;2-P, 9790291.
2. Speight PM, Barrett AW. Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg 2009, 47(8):587-593. 10.1016/j.bjoms.2009.03.017, 19409681.
3. Hocwald E, Korkmaz H, Yoo GH, Adsay V, Shibuya TY, Abrams J, Jacobs JR. Prognostic factors in major salivary gland cancer. Laryngoscope 2001, 111(8):1434-1439. 10.1097/00005537-200108000-00021, 11568581.
4. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-1785. 10.1093/jnci/djj495, 17179479.
5. Cariati M. Evaluating the link between stem cells and breast cancer. Expert Rev Anticancer Ther 2008, 8(8):1313-1322. 10.1586/14737140.8.8.1313, 18699767.
6. Oliveira L, Jeffrey S, Ribeiro-Silva A. Stem cells in human breast cancer. Histol Histopathol 2010, 25(3):371-385.
7. Umezawa A, Gorham JD. Dueling models in head and neck tumor formation. Lab Invest 2010, 90(11):1546-1548. 10.1038/labinvest.2010.165, 21030945.
8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401. 10.1038/nature03128, 15549107.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-115. 10.1038/nature05384, 17122771.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
11. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65(20):9328-9337. 10.1158/0008-5472.CAN-05-1343, 16230395.
12. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
13. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25(12):1696-1708. 10.1038/sj.onc.1209327, 16449977.
14. Shtivelman E, Bishop JM. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991, 11(11):5446-5453. 361913, 1922057.
15. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998, 34(3):162-168. 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K, 9492843.
16. Assimakopoulos D, Kolettas E, Patrikakos G, Evangelou A. The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas. Histol Histopathol 2002, 17(4):1269-1281.
17. Kristiansen G, Machado E, Bretz N, Rupp C, Winzer KJ, König AK, Moldenhauer G, Marmé F, Costa J, Altevogt P. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest 2010, 90(7):1102-1116. 10.1038/labinvest.2010.70, 20351695.
18. Heider KH, Dämmrich J, Skroch-Angel P, Müller-Hermelink HK, Vollmers HP, Herrlich P, Ponta H. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993, 53(18):4197-4203.
19. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993, 53(20):4754-4756.
20. Sato S, Miyauchi M, Takekoshi T, Zhao M, Kudo Y, Ogawa I, Kitagawa S, Fujita M, Takata T. Reduced expression of CD44 variant 9 is related to lymph node metastasis and poor survival in squamous cell carcinoma of tongue. Oral Oncol 2000, 36(6):545-549. 10.1016/S1368-8375(00)00049-X, 11036249.
21. Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J, Sironen R, Juhola M, Kumpulainen E, Johansson R, Nuutinen J, Kosma VM. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol 2007, 43(1):51-59. 10.1016/j.oraloncology.2006.01.003, 16798062.
22. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104(3):973-978. 10.1073/pnas.0610117104, 1783424, 17210912.
23. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005, 11(18):6574-6581. 10.1158/1078-0432.CCR-05-0606, 16166435.
24. Lim SC. CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 2005, 59(Suppl 2):S351-S354.
25. Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58(2):183-192. 10.1002/pros.10324, 14716744.
26. Barnes L, Everson J, Reichart P, Sidransky D. Pathology and Genetics or Head and Neck Tumours. " World Health Organization Classification of Tumours 2005, 209-281. Lyon: IARC Press, Kleihues P, Sobin LH.
27. Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. " TNM Atlas" 2005, 61-65. New York: Springer Verlag, Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH.
28. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10(3):R53. 10.1186/bcr2108, 2481503, 18559090.
29. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003, 9(13):4906-4913.
30. Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 2002, 128(8):904-908.
31. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010, 74(2):134-148. 10.1016/j.critrevonc.2009.10.004, 19939701.
32. Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005, 63(7):917-928. 10.1016/j.joms.2005.03.006, 16003616.
33. Lima RA, Tavares MR, Dias FL, Kligerman J, Nascimento MF, Barbosa MM, Cernea CR, Soares JR, Santos IC, Salviano S. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005, 133(5):702-708. 10.1016/j.otohns.2005.08.001, 16274796.
34. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997, 50(2):57-71. 10.1136/mp.50.2.57, 379585, 9231152.
35. Oliveira-Costa JP, Zanetti JS, Silveira GG, Soave DF, Oliveira LR, Zorgetto VA, Soares FA, Zucoloto S, Ribeiro-Silva A. Differential expression of HIF-1alpha in CD44 + CD24-/low breast ductal carcinomas. Diagn Pathol 2011, 6:73. 10.1186/1746-1596-6-73, 3170242, 21824412.
36. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009, 15(18):2258-2264. 10.3748/wjg.15.2258, 2682242, 19437567.
37. Oliveira LR, Oliveira-Costa JP, Araujo IM, Soave DF, Zanetti JS, Soares FA, Zucoloto S, Ribeiro-Silva A. Cancer stem cell immunophenotypes in oral squamous cell carcinoma. J Oral Pathol Med 2010, 40:135.
38. Gun BD, Bahadir B, Bektas S, Barut F, Yurdakan G, Kandemir NO, Ozdamar SO. Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagn Pathol 2012, 7:80. 10.1186/1746-1596-7-80, 3407727, 22784357.
39. Fonseca F, Moura Nunes JF, Soares J. Expression of CD44 isoforms in normal salivary gland tissue: an immunohistochemical and ultrastructural study. Histochem Cell Biol 2000, 114(6):483-488.
40. Franchi A, Moroni M, Paglierani M, Santucci M. Expression of CD44 standard and variant isoforms in parotid gland and parotid gland tumours. J Oral Pathol Med 2001, 30(9):564-568. 10.1034/j.1600-0714.2001.300910.x, 11555161.
41. Zhou Q, Chang H, Zhang H, Han Y, Liu H. Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis. Diagn Pathol 2012, 7:119. 10.1186/1746-1596-7-119, 3487809, 22963430.
42. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis 2002, 8(5):229-240. 10.1034/j.1601-0825.2002.02870.x, 12363107.
43. Ghazy SE, Helmy IM, Baghdadi HM. Maspin and MCM2 immunoprofiling in salivary gland carcinomas. Diagn Pathol 2011, 6:89. 10.1186/1746-1596-6-89, 3191357, 21943228.
44. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008, 68(8):2803-2812. 10.1158/0008-5472.CAN-07-6463, 18413748.
45. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P, Sthoeger ZM. CD24 is a marker for human breast carcinoma. Cancer Lett 1999, 143(1):87-94. 10.1016/S0304-3835(99)00195-0, 10465342.
46. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998, 12(12):1241-1251.
47. Shirasawa T, Akashi T, Sakamoto K, Takahashi H, Maruyama N, Hirokawa K. Gene expression of CD24 core peptide molecule in developing brain and developing non-neural tissues. Dev Dyn 1993, 198(1):1-13. 10.1002/aja.1001980102, 8292828.
48. Akashi T, Shirasawa T, Hirokawa K. Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch 1994, 425(4):399-406.
49. Nanduri LS, Maimets M, Pringle SA, van der Zwaag M, van Os RP, Coppes RP. Regeneration of irradiated salivary glands with stem cell marker expressing cells. Radiother Oncol 2011, 99(3):367-372. 10.1016/j.radonc.2011.05.085, 21719134.
50. Ma YQ, Geng JG. Obligatory requirement of sulfation for P-selectin binding to human salivary gland carcinoma Acc-M cells and breast carcinoma ZR-75-30 cells. J Immunol 2002, 168(4):1690-1696.
51. Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008, 39(7):1096-1102. 10.1016/j.humpath.2007.12.003, 18495204.
52. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11(3):1154-1159.
53. Pandit TS, Kennette W, Mackenzie L, Zhang G, Al-Katib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL, Rodenhiser DI. Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 2009, 35(2):297-308.
54. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 2011, 28(3):745-752. 10.1007/s12032-010-9530-3, 20405247.
55. Carrillo JF, Maldonado F, Carrillo LC, Ramirez-Ortega MC, Pizano JG, Melo C, Chanona JG, Luna-Ortiz K, Ocaña LF. Prognostic factors in patients with minor salivary gland carcinoma of the oral cavity and oropharynx. Head Neck 2011, 33(10):1406-1412. 10.1002/hed.21641, 21928413.
56. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 2008, 14(24):3903-3907. 10.3748/wjg.14.3903, 2721450, 18609717.
57. Gorjup E, Danner S, Rotter N, Habermann J, Brassat U, Brummendorf TH, Wien S, Meyerhans A, Wollenberg B, Kruse C. Glandular tissue from human pancreas and salivary gland yields similar stem cell populations. Eur J Cell Biol 2009, 88(7):409-421. 10.1016/j.ejcb.2009.02.187, 19410331.